The case for & against
Bull & Bear analysis
Bearish
Beyond Air, Inc. (NASDAQ: XAIR) is a medical technology company that specializes in innovative inhaled nitric oxide delivery systems targeted at treating respiratory diseases. The company is notable for its primary product, LungFit PH, which enhances treatment protocols in various clinical settings, particularly in hospitals. Beyond Air is strategically expanding its market presence both in the U.S. and internationally while also working towards the introduction of a second-generation system, positioning itself within the rapidly evolving healthcare technology space.
Bull says
- ↑Q1 revenue $7.7 M, up 107% YoY, driven by LungFit PH adoption
- ↑Customer renewals exceed 90%, with rising multi-year hospital contracts
- ↑Q1 gross profit reached $300 K after 37% SG&A cut
- ↑GPO agreements with Premier and Vizient grant access to ~3,000 hospitals
- ↑Gen-2 system launch expected late 2026 to expand market share
- ↑High liquidity factor and sensitivity to oil prices suggest financial flexibility
Bear says
- ↓FY26 net cash burn $19.1 M, pressuring liquidity despite 56% reduction
- ↓Gen-2 FDA approval timing unclear, risking launch delays
- ↓Heavy reliance on new hospital contracts exposes revenue to procurement cycles
- ↓Negative earnings yield and weak profitability factors underscore valuation risk
- ↓Stiff competition from established cylinder-based therapeutics could limit market share
- ↓Elevated leverage risk and high short interest reflect investor concern
Earnings Call · Q3 2025 · Mgmt. Guidance
Updated 07-05-2026neutral
Transcript signals
Bull points
- We have achieved several significant milestones, strengthened our balance sheet to support continued commercial execution, and made a strategic decision to sell our Neuronoff subsidiary in exchange for equity in the acquiring company at up to $32.5 million in upfront development and commercial milestone payments.
- revenue in the fiscal quarter increased 105% year-over-year to $2.2 million. This represents continued progress as we scale adoption and expand awareness of LungFit PH in clinical settings.
- Customer feedback has been encouraging, with retention exceeding 90% and more than half of customers under multi-year agreements.
Bear points
- Net loss attributed to common stockholders of Beyond Air was $7.3 million, or a loss of 85 cents per share, basic and diluted, compared with 13 million, or a loss of $2.96 per share, basic and diluted.
- Net loss attributed to common stockholders of Beyond Air was $7.3 million, or a loss of 85 cents per share, basic and diluted, compared with 13 million, or a loss of $2.96 per share, basic and diluted.
- Yeah, I think Dan's right in what he says, but I would, you know, there are a couple of factors, and like Dan said, he's barely two months in. There are a couple of factors that we're still trying to figure out with respect to the, to the margin on, and that will be from a pricing side of the market. So I think, you know, that goal of 70% with the gen two is a great goal. That's target, you know, if it's 65 and 65, you know, that's not the end of the world for us, but I think that's our target. And I think we'd like to hit it and, you know, target with gen one would be to get close to 60. But again, I think a gen one, you know, is more of a 50s type thing. But again, it's going to depend on how the price shakes out in the market at the end of the day. And, you know, that remains to be seen.
Read full transcript analysis ›